Key points from article :
GRAIL is a healthcare company whose mission is to detect cancer early when it can be cured.
Expects to introduce Galleri, its multi-cancer early detection blood test, in the second quarter of 2021.
Completed its second independent Data and Safety Monitoring Board review.
Data support Galleri’s introduction as a laboratory developed test (LDT).
“Cancer remains the second-leading cause of death in large part because we lack recommended screening tests," - Hans Bishop, chief executive officer at GRAIL.
“...significant early interest in Galleri from health systems, medical practices, and self-insured employers.”
Galleri can determine where in the body the cancer is located with high accuracy, all from a single blood draw.
Available under investigational use in PATHFINDER, where it is being used to guide clinical care.
Expected to be offered to eligible patients in the United Kingdom (UK) starting in 2021 for earlier cancer diagnoses.
